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Vitamin B6 requirements of patients on chronic peritoneal dialysis.
Patients with chronic renal failure often develop vitamin B6 deficiency,
which is of clinical concern because the multiorgan system manifesta-
tions are similar to those of uremia. Vitamin B6 deficiency in hemodi-
alysis patients has been previously studied, but the need for daily
pyridoxine supplementation in patients on chronic peritoneal dialysis(CPD) remains unclear. Therefore, we studied a group of 11 stable
patients, nine on CAPD and two CCPD, to test for vitamin B6
deficiency and to establish daily requirements. Adequacy of vitamin B6
nutrition was assessed by measurement of plasma and dialysate effluent
total vitamin B6 and pyridoxal 5'-phosphate (PLP), the latter using a
very sensitive modification of the tyrosine apodecarboxylase enzyme
assay. After four weeks without vitamin B6 supplements on a diet
containing 1.3 0.2 mg vitamin B6/day (7.7 1.2 imol/day), all
patients had subnormal plasma PLP levels, 16 3 nmol/liter (nml 40 to
60), seven having a severe deficiency (n20 nmol/liter). Plasma total
vitamin B6 levels (which includes non-PLP forms of the vitamin) were
normal in all patients at baseline, 116 29 nmol/liter. Peritoneal losses
were small, 8 2 nmol PLP/day and 545 61 nmol total vitamin
B6/day. Supplementation with 5 mg/day oral pyridoxine HCI for up to
16 weeks adequately repleted eight patients (65 7 nmol PLP/L), while
three patients required 10mg/day to achieve normal plasma PLP levels.
During three episodes of peritonitis, dialysate losses of PLP did not
increase. These data indicate that in these CPD patients: (I) dietary
intake of vitamin B6 is inadequate to prevent significant deficiency; (2)
low plasma PLP levels may be caused by impaired phosphorylation of
precursor forms or increased degradation of PLP, not by the negligible
losses into peritoneal dialysate; and (3) 10 mg of daily oral pyridoxine
hydrochloride supplementation restores plasma PLP levels to normal
and is the recommended dose for these patients.
Vitamin B6 (commonly administered as pyridoxine HCI) is a
water-soluble essential nutrient which is important for the
normal function of multiple organ systems. It is metabolized to
the active molecule, pyridoxal 5'-phosphate (PLP), which
serves as a coenzyme for many diverse biochemical reactions
[lb The possibility of vitamin B6 deficiency developing in
dialysis patients has been of clinical interest because many of
the signs and symptoms of this deficiency (that is, immune
dysfunction, altered lipid and amino acid metabolism, derma-
tologic disorders, and peripheral neuropathy [2—7]) are similar
to and can be erroneously attributed to those of uremia.
The need for vitamin B6 supplementation has been demon-
strated previously in some studies of hemodialysis and inter-
mittent peritoneal dialysis patients [2, 3, 8—13]. Based on these
reports, the recommended oral dose of pyridoxine HCI has
varied between none, 10mg and 300mg per day [2, 3, 8, 10, 11,
14]. The wide range of recommendations for vitamin B6 sup-
plementation may be at least in part due to differences in the
methods used to measure vitamin B6 nutrition.
The purpose of this study was to examine the effect of
chronic peritoneal dialysis (CPD) on vitamin B6 requirements.
To accomplish this objective, we studied a group of stable CPD
patients by using very sensitive PLP and total vitamin B6
assays in an effort to a) establish the minimum daily require-
ment of oral pyridoxine HCI and b) determine peritoneal losses
of these vitamers with and without peritonitis.
Methods
Patient population
Patients were recruited from the Long Beach VA Medical
Center CPD population. Informed consent was obtained, as
approved by the Human Studies Protection Committee. Pa-
tients were excluded from the study if they were on peritoneal
dialysis for less than three months, had an episode of peritonitis
within 30 days of the initiation of the protocol, had a history of
gastrointestinal malabsorption, were being treated with pyri-
doxine antagonists (such as hydralazine or isoniazid) or were
unable to provide a reliable dietary diary. Eleven male patients
participated in the study, nine were on CAPD and two on
CCPD, Their ages ranged from 26 to 70 years, and they were on
the CPD modality 23 4 months (range 4 to 50 months). None
of the patients were smokers. The etiology of their renal disease
included nephrosclerosis (4), glomerulonephritis (4), polycystic
kidney disease (2), and chronic pyelonephritis (1).
Protocol
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All vitamin supplements containing pyridoxine were discon-
tinued at least four weeks prior to the study. Other supplemen-
tal vitamins were unchanged. Patients were continued on their
normally prescribed renal diet designed to provide approxi-
mately 1.3 g protein/kg/day. The nutrient intake was calculated
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using standard nutrition tables [15]. Then, a baseline three-day
dietary diary was recorded and fasting blood and peritoneal
effluent samples obtained. All blood samples were immediately
centrifuged, and the plasma, serum and dialysate samples were
stored at —30°C until assayed. Plasma was used to determine
levels of PLP and total vitamin B6, and serum was measured for
alkaline phosphatase, GOT, GPT, BUN, creatinine, LDH, total
protein and albumin. Aliquots from the effluents of all ex-
changes for the 24 hours prior to the blood sampling were
pooled and measured for PLP, total vitamin B6, total protein
and alkaline phosphatase. At the end of the four week supple-
ment-free period, those patients who had subnormal plasma
PLP levels [16] (<40 nmol/liter) were supplemented with oral
pyridoxine HC1, beginning with a single daily dose of 5 mg (29.8
prnol; provided by Dr. Bhagavan, Hoffmann-La Roche Inc.,
Nutley, New Jersey, USA). At monthly intervals the plasma
and dialysate effluent studies were repeated and the pyridoxine
HCI dose was increased by 5 mg daily increments in order to
achieve normal [16] plasma PLP concentrations. During epi-
sodes of peritonitis, additional samples of plasma and effluent
were obtained within 48 hours of presentation. Another three-
day dietary diary was recorded at the conclusion of the 16 week
study.
Laboratory assays
Plasma and dialysate PLP determinations were made in
duplicate in one author's (RDR) laboratory, after de-proteiniza-
tion with tnchloroacetic acid, by use of a previously described
modification of the L-tyrosine apodecarboxylase enzyme assay
[17]. The normal plasma PLP levels by this method are 40 to 80
nmollliter, with a sensitivity of 1 nmol/liter. The inter- and
intra-assay coefficients of variation are 11.0 and 3.4%, respec-
tively. The plasma and dialysate total vitamin B6 concentra-
tions were determined by a microbiological growth stimulation
assay using Saccharomyces uvarum (ATCC 9080) as the test
organism [18]. The inter- and intra-assay coefficients of varia-
tion for the microbiological assay are 10.1 and 3.7%, respec-
tively. Serum GOT, GPT, total protein, alkaline phosphatase,
albumin, SUN, and creatinine were assayed on a Technicon
autoanalyzer (Technicon Corp. Terrytown, New Jersey). The
protein content of the dialysate was measured using the tn-
chloroacetic acid method (ACAIII, Dupont, Wilmington, Del-
aware, USA) with a sensitivity to 1.0 mg/dl. Dialysate alkaline
phosphatase was assayed with the nitrophenyl phosphate
method (Baker Instruments, Allentown, Pennsylvania, USA)
with a sensitivity to 2 mU/mI.
Statistics
The data were examined by analysis of variance (ANOVA)
for repetitive measures and coefficient of correlation. The
results were expressed as the mean SE, and a P value <0.05
was considered statistically significant.
Results
Baseline studies
The dietary intake of vitamin B6 was 1.3 0.2 and 1.1 0.1
mg/day (7.7 1.2 and 6.5 0.6 mol/day) on the two separate
dietary records, which were 59% and 50%, respectively, of the
RDA of 2.2 mg/day for men. The energy (excluding dialysate
glucose absorption) and protein intakes were 20 1 kcal/
kg/day, and 0.8 0.1 g/kg/day, respectively. The protein and
vitamin B6 intakes were significantly correlated (r =0.60, P <
0.05). There was no significant correlation between the dietary
vitamin B6 intake and the baseline plasma PLP levels (P >
0.05). Plasma PLP concentrations at the end of the baseline
period were 16 3 nmol/liter, and were abnormally low (<40
nmol/liter) in all patients. Seven of 11(63%) patients had plasma
PLP levels <20 nmol/liter. Plasma total vitamin B6 concentra-
tions, however, were normal (>60 nmol/liter) in all individuals,
116 29 nmol/liter. The peritoneal PLP losses averaged only
1.9 0.4 pjg/day (8 2 nmollday), and peritoneal total vitamin
B6 were also small at 545 61 nmol/day; neither correlated
with the 8.2 0.8 g/day dialysate protein loss (P > 0.05).
Dialysate alkaline phosphatase activity was measured in seven
patients, ranging from 2 to 19 mU/ml. Serum GOT and GPT
activities were normal at 19 4 and 24 4 mU/mi, respec-
tively. Serum GOT and GPT activities, albumin and total
protein levels did not significantly correlate with plasma PLP
concentrations. Baseline serum alkaline phosphatase was 174
67 mU/mI, and was elevated in only 4 of the II patients. There
was no correlation between the baseline plasma PLP level and
serum alkaline phosphatase activity (r = —0.35, P > 0.05).
There was also no correlation between duration of CPD and
baseline plasma PLP levels (P> 0.05).
Supplementation studies
The mean plasma PLP levels were normalized (65 7
nmol/liter) with a 5 mg/day supplement of pyridoxine HCI in 8
of the 11 patients (Group A) at the end of four weeks, and
remained so throughout the remainder of the 16 week study
period (P < 0.0005; Fig. 1, Table I). Plasma total vitamin B6
increased to 304 66 nmol/liter at the end of 16 weeks (P <
0.0005). The dose of pyridoxine HCI was increased to 10
mg/day in the remaining three patients (Group B) because their
plasma PLP levels remained abnormally low, 23 5 nmol/Iiter,
(P < 0.001, compared to Group A) at the end of eight weeks of
5 mg daily pyridoxine HC1 supplementation. The plasma PLP
levels then normalized in two of these patients by week 12 (45
and 55 nmol/liter) and in the remaining patient by week 16 (40
nmol/liter). Corresponding plasma total vitamin B6 values in
these three patients showed increases to 368, 305, and 293
nmol/liter, respectively. It should be noted that one patient
could not take supplemental pyridoxine HCI because of a
severe intercurrent illness, and the plasma PLP level dropped
from 45 nmol/liter at week 12 to 26 nmol/liter at week 16. At the
end of the 16 week study (mean plasma PLP levels for all
patients 52 7 nmol/liter), serum GOT and GPT activities were
21 5 and 26 6 mU/mi, respectively, which was not
significantly different from the baseline levels (P > 0.05).
Effect of peritonitis
Three patients experienced a single episode of peritonitis
during the course of the study. There was a 58% increase in
dialysate protein losses from an average of 8.1 g/day at baseline
to 12.8 g/day during peritonitis. However, during two episodes,
PLP was undetectable in the dialysate. In the remaining patient,
dialysate PLP was 5.2 p.g/day (21.0 nmol/day). Another patient
had nausea, vomiting and diarrhea. His dietary B6 intake
decreased to <1.5 mg/day and he did not take his vitamin B6
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Fig. 1. Plasma PLP levels during pyridoxine
HCI replacement therapy. Shaded bars
indicate Group A (5 mg/day). Hatched bars
indicate Group B (supplementation increased
to 10 mg/day at week 8). *J < 0.0005; ** P <
0.001.
Table 1. Plasma PLP and total vitamin B6 levels (nmol/liter)
# Baseline Week 4 Week 8 Week 12 Week 16
Group A
Group B
All Pts
8
3
11
PLP
B6
PLP
B6
PLP
B6
17 4
116 12
14 5
116 17
16 3
116 9
65 7
248 20
20 1
215 42C
52 8
240 l8
60 5
280 34
23 5
229 30C
50 7
266 27
57 l0
295 2?
45 6b
320 2?
54 7
301 19
56 9
304 2?
40 gb
412 112C
52 7
337 37a
Group A = 5 mg/day pyridoxine HCI.
Group B = dose increased to 10 mg/day after week 8.
a P < 0.0005 compared with Baselineb p < 0.001 compared with BaselineP < 0.05 compared with Baseline
supplement for the first two days of peritonitis. His plasma PLP
levels decreased to subnormal values, from 18 to 10 nmol/liter.
Plasma PLP levels remained within normal limits in the other
two patients.
Discussion
Of the major mammalian forms of vitamin B6 only the
metabolite PLP is active and serves as the coenzyme necessary
for the normal function of many organ systems [19]. There has
been particular concern about vitamin B6 deficiency in patients
with end-stage renal disease because many of the symptoms of
this deficiency are similar to and could hypothetically contrib-
ute to those of uremia [91. Proposed mechanisms for altered
vitamin B6 metabolism specific to uremia have included inade-
quate intake or absorption, loss by dialysance, inhibition of the
action or metabolism of PLP by uremic toxins, impaired pyri-
doxal kinase-mediated phosphorylation of pyridoxal or in-
creased degratory pyridoxal phosphate phosphatase activity [2,
9, 10]. A major problem in studying vitamin B6 nutrition has
been methodological [17]. For example, early studies which
measured serum PLP-dependent enzymes (such as GOT) or
used microbiological assays may have been inaccurate [14,
19—22].
Few studies have investigated vitamin B6 nutrition in perito-
neal dialysis patients. Kopple et al [8] using an erythrocyte
assay, recommended 5 or 10 mg/day of oral pyndoxine HCI
supplementation for patients on IPD. Henderson, Leung and
Shenkin [12] demonstrated normal EGOT indices in nine CAPD
patients on 50 mg/day pyridoxine. Stockberger et al [13] dem-
onstrated that pediatric CAPD patients had minimal dialysate
losses, and low plasma PLP levels were repleted by as little as
2 mg/day of pyridoxine supplementation.
In the 11 patients on CPD described in the present study, PLP
levels were assessed by a modification of the L-tyrosine apo-
decarboxylase enzyme assay [17] with a sensitivity to 1 nmol/
liter concentration. Four weeks off of pyridoxine supplementa-
tion, all 11 of the male CPD patients had low levels of plasma
PLP. Baseline plasma PLP levels in 63% of these individuals
were <20 nmol/liter which is indicative of a severe deficiency
[16]. The normal plasma levels of total vitamin B6 strongly
supports the hypothesis that PLP deficiency is due to impaired
oxidation or phosphorylation of the inactive precursor com-
pounds or to increased hydrolysis of the PLP to (inactive)
pyridoxal, increasing the daily vitamin B6 requirement of CPD
patients when compared to nonuremic individuals. The pa-
tients' intake of only 59% of the RDA of 2.2 mg/day dietary
vitamin B6 was a relatively small contributing factor to the
vitamin deficiency. This reflects decreased intake because of
the uremia as well the relatively low amounts in typical Western
diets (approximately 1.6 mg/day for men in this age range [23]).
Three of 11 patients (27%) supplemented with 5 mg of pyridox-
inc HCI (which supplies 4.1 mg of pyridoxine) were still vitamin
B6 deficient. Ten mg/day of pyridoxine HCI was necessary to
achieve normal plasma PLP levels in these patients. This is of
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clinical importance since prior studies did not clearly define the
minimum dose necessary in this patient population. Adequate
plasma PLP persisted to the conclusion of the study, for up to
16 weeks (Fig. 1). Serum activities of the PLP-dependent GOT
and GPT enzymes were not adequate indicators of vitamin B6
nutrition. SGOT and SGPT activities were normal at baseline
and did not correlate with the degree of pyridoxine supplemen-
tation.
Low plasma PLP levels could not be attributed to losses in
the peritoneal effluent since only 7.7 1.6 nmol/day was
recovered in the dialysate (less than 0.03% of the total vitamin
B6 ingested in the diet and supplement). The amount of PLP
losses decreased during episodes of peritonitis despite in-
creased protein losses. It is theoretically possible that under
these circumstances effluent levels of PLP could have been
misleadingly low because of PLP degradation by peritoneal
leukocytes. However, total vitamin B6 concentrations were not
determined on dialysate samples obtained during peritonitis.
Plasma PLP levels decreased slightly in one of three patients
during these brief episodes of infection. However, we have data
in only three episodes of peritonitis, and the amount of pyri-
doxine needed during illnesses known to increase the vitamin
B6 requirement has yet to be established.
Other mechanisms have been proposed by which vitamin B6
deficiency could occur in stable CPD patients. For example,
circulating alkaline phosphatase, which often is elevated in
uremic patients because of secondary hyperparathyroidism,
might degrade significant quantities of PLP [24, 25]. Reynolds,
Moser-Veillon and Kant [26] recently reported that slight ele-
vations of alkaline phosphatase activity over prolonged periods
of time may cause a low plasma PLP level in the elderly, even
though the activity levels for the alkaline phosphatase often
remain within the reference ranges. This may not be relevant in
the present study in that the baseline low plasma PLP levels
were not significantly correlated with the high serum alkaline
phosphatase concentrations. In addition, Spannuth eta! [10] did
not find a correlation between the levels of these two com-
pounds. However, Coburn and Whyte [25] have suggested that
tissue nonspecific alkaline phosphatase is an ectoenzyme which
regulates extracellular (serum) concentrations of PLP, while
having little influence on intracellular concentrations.
The benefits of assessing vitamin B6 deficiency by PLP levels
are still being debated [27] despite numerous studies with
conflicting results when using the various erythrocyte ami-
notransferase assays [28, 29]. Vitamin B6 deficiency in hemo-
dialysis patients has been suggested by low erythrocyte GOT or
GPT activities, their supranormal elevation in response to
incubation with PLP substrate (that is, increased EGOT or
EGPT indices) [2, 8], and correction with supplemental pyri-
doxine [8]. However, erythrocyte indices can be influenced by
factors other than vitamin B6 deficiency [3], such as the
chronicity of the deficiency, decreased apoenzyme levels, or
altered erythrocyte age. For example, erythrocyte index values
reportedly have not correlated with absolute plasma or eryth-
rocyte levels [9], or pyridoxine-responsive immune abnormali-
ties [7]. In the present study, we chose to use the PLP assay
because [27]: 1) Plasma PLP concentration correlated strongly
with skeletal muscle PLP content in the rat [30]; 2) plasma PLP
has reflected its tissue concentration over a wide range of
dietary intakes [30], unlike that of the measurements of the
serum or erythrocyte aminotransferases [17]; 3) plasma PLP
levels decreased when patients are fed a vitamin B6 deficient
diet and normalize when pyridoxine is supplemented; 4) plasma
PLP levels correlated with unnary indices of vitamin B6 nutri-
tion such as 4-pyridoxic acid and total vitamins B6 [161; and 5)
pyridoxine supplements increased plasma PLP by a half-life of
10 days as compared to over 30 days for EGOT and EGPT
activity [31]. Nevertheless, there still have been no studies to
correlate plasma PLP levels with intracellular concentrations of
vitamin B6 in humans. Low plasma PLP values have previously
been reported in hemodialysis patients [9—111. However, the
observation of adequate concentrations of all B6 vitamins (total
vitamin B6) suggests that there is an adequate supply of vitamin
B6 but that normal concentrations of PLP are not being
maintained in these patients.
Thus, in these 11 CPD patients: 1) dietary vitamin B6 intake
did not maintain normal plasma PLP levels and led to an
apparent severe deficiency; 2) low plasma PLP levels may be
due to impaired oxidation or phosphorylation of precursors or
to enhanced hydrolysis into pyridoxal by membrane-bound
alkaline phosphatase, not because of peritoneal losses; and 3)
based on normalization of plasma PLP levels, it is recom-
mended that patients receiving chronic peritoneal dialysis be
supplemented with 10 mg per day of oral pyridoxine HC1.
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